Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Sep 28.

Published in final edited form as: ACS Appl Mater Interfaces. 2011 Aug 26;3(9):3316–3324. doi: 10.1021/am2004366

A: Plot showing SERS enhancement in the presence of 10⁴ cells/mL SK-BR-3 breast cancer cell. B) Plot showing SERS scattering intensity change at 1590 cm⁻¹ upon the addition of different concentrations (number of cells/mL) of SK-BR-3, MDA-MB human breast cancerous and HaCaT normal skin cells to S6 aptamer conjugated GNPOP attached SWCNTs. In all cases, we have used 10 µg/mL SWCNT and 10 µg/mL SWCNT hybrid.

A: Plot showing SERS enhancement in the presence of 10⁴ cells/mL SK-BR-3 breast cancer cell. B) Plot showing SERS scattering intensity change at 1590 cm⁻¹ upon the addition of different concentrations (number of cells/mL) of SK-BR-3, MDA-MB human breast cancerous and HaCaT normal skin cells to S6 aptamer conjugated GNPOP attached SWCNTs. In all cases, we have used 10 µg/mL SWCNT and 10 µg/mL SWCNT hybrid.